Literature DB >> 25664024

Analysis of prognostic factors and comparison of prognostic index scores in patients with brain metastases after whole-brain radiotherapy.

Judong Luo1, Hong Zhu2, Yiting Tang1, Honglin Wang2, Xifa Zhou1, Xujing Lu1, Shuyu Zhang3, Yunhai Li2.   

Abstract

BACKGROUND AND
PURPOSE: Brain metastases (BMs) are typically associated with poor patient prognosis. Radiation therapy remains the primary treatment for BMs, and patient's prognosis is affected by many factors. The aim of this study was to identify prognostic factors and to compare prognostic index scores in patients with BMs who received whole-brain radiotherapy (WBRT).
METHODS: A retrospective prognostic study was conducted in 125 patients with BMs who underwent WBRT between Jan 2008 and Jul 2011. The significance of prognostic variables with regard to survival was determined using univariate and multivariate analyses. A prognostic index (PI) was established based on Cox regression analysis and subgrouping values. The recursive partitioning analysis classes (RPA), basic score for brain metastases (BS-BM), Graded Prognostic Assessment index (GPA), and PI were assessed with regard to prognosis.
RESULTS: The median survival time was 213 days (7.1 months). In the univariate analysis of the test group, survival was significantly associated with Karnofsky performance status (KPS) score, the number of BMs, the presence of extracranial metastases, primary tumor status and the number of involved extracranial organs. The multivariate analysis showed that the KPS score (P = 0.002, Wald = 9.700), presence of extracranial metastases (P = 0.018, Wald = 5.604) and primary tumor status (P = 0.001, Wald = 10.212) were significantly correlated with overall survival. RPA, BS-BM and GPA were all closely related to prognosis, as determined using a log-rank test. In predicting the 3- and 6-month survival for patients, the PI was superior to the other three modes.
CONCLUSIONS: The three indexes, RPA, BS-BM and GPA, are valid prognostic index models; however, the PI model was the most powerful.

Entities:  

Keywords:  Neoplasms; brain metastases; prognosis; prognostic index scores; whole-brain radiotherapy

Year:  2014        PMID: 25664024      PMCID: PMC4307471     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  27 in total

1.  A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.

Authors:  Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-10       Impact factor: 7.038

2.  Subclassification of recursive partitioning analysis Class II patients with brain metastases treated radiosurgically.

Authors:  Masaaki Yamamoto; Yasunori Sato; Toru Serizawa; Takuya Kawabe; Yoshinori Higuchi; Osamu Nagano; Bierta E Barfod; Junichi Ono; Hidetoshi Kasuya; Yoichi Urakawa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-29       Impact factor: 7.038

3.  Prognostic indexes for brain metastases: which is the most powerful?

Authors:  Gustavo Arruda Viani; Lucas Godói Bernardes da Silva; Eduardo Jose Stefano
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-07-01       Impact factor: 7.038

4.  Institutional, retrospective analysis of 777 patients with brain metastases: treatment outcomes and diagnosis-specific prognostic factors.

Authors:  Delphine Antoni; Jean-Baptiste Clavier; Marius Pop; Catherine Schumacher; François Lefebvre; Georges Noël
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-04-11       Impact factor: 7.038

5.  Prediction of short survival in patients with brain metastases based on three different scores: a role for 'triple-negative' status?

Authors:  C Nieder; A Pawinski; M Molls
Journal:  Clin Oncol (R Coll Radiol)       Date:  2009-09-16       Impact factor: 4.126

Review 6.  Brain metastases.

Authors:  Jaime Gállego Pérez-Larraya; Jerzy Hildebrand
Journal:  Handb Clin Neurol       Date:  2014

7.  Prognostic scores in patients with brain metastases from non-small cell lung cancer.

Authors:  Carsten Nieder; Roy M Bremnes; Nicolaus H Andratschke
Journal:  J Thorac Oncol       Date:  2009-11       Impact factor: 15.609

8.  Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

Authors:  James W Welsh; Ritsuko Komaki; Arya Amini; Mark F Munsell; Wyatt Unger; Pamela K Allen; Joe Y Chang; Jeffrey S Wefel; Susan L McGovern; Linda L Garland; Su S Chen; Jamie Holt; Zhongxing Liao; Paul Brown; Erik Sulman; John V Heymach; Edward S Kim; Baldassarre Stea
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

9.  Brain metastasis. Prognostic value of the number of involved extracranial organs.

Authors:  D Rades; L Gerdan; B Segedin; V Nagy; M T Khoa; N T Trang; S E Schild
Journal:  Strahlenther Onkol       Date:  2013-10-10       Impact factor: 3.621

10.  Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases.

Authors:  L Dziggel; B Segedin; N H Podvrsnik; I Oblak; S E Schild; D Rades
Journal:  Strahlenther Onkol       Date:  2013-03-23       Impact factor: 3.621

View more
  3 in total

1.  Comparison of Prognostic Indices in NSCLC Patients with Brain Metastases after Radiosurgery.

Authors:  Hong Xiang Gao; Shi Gao Huang; Jian Fei Du; Xue Cheng Zhang; Nan Jiang; Wen Xing Kang; Jian Mao; Qi Zhao
Journal:  Int J Biol Sci       Date:  2018-11-03       Impact factor: 6.580

2.  Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis.

Authors:  Yunyun Lu; Yun Fan
Journal:  Onco Targets Ther       Date:  2016-03-09       Impact factor: 4.147

3.  The prognostic factors influencing overall survival in uterine cervical cancer with brain metastasis.

Authors:  Hyera Kim; Kang Kook Lee; Mi Hwa Heo; Jin Young Kim
Journal:  Korean J Intern Med       Date:  2018-10-26       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.